Capecitabine + Epirubicin + Cyclophosphamide Combination Therapy (CEX Therapy) as Neoadjuvant Chemotherapy for HER-2-Negative Breast Cancer: A Retrospective, Single-Center Study
-
- Yokoyama Tadashi
- Department of Surgery, Nippon Medical School Tama Nagayama Hospital
-
- Makino Hiroshi
- Department of Surgery, Nippon Medical School Tama Nagayama Hospital
-
- Seki Natsuki
- Department of Surgery, Nippon Medical School Tama Nagayama Hospital
-
- Ueda Junji
- Department of Surgery, Nippon Medical School Tama Nagayama Hospital
-
- Hosone Masaru
- Department of Pathology, Nippon Medical School Tama Nagayama Hospital
-
- Katayama Hironori
- Department of Pathology, Nippon Medical School Tama Nagayama Hospital
-
- Takei Hiroyuki
- Department of Breast Surgical Oncology, Nippon Medical School
-
- Yoshida Hiroshi
- Department of Gastroenterological Surgery, Nippon Medical School
Search this article
Abstract
<p>Background: We modified and administered capecitabine + epirubicin + cyclophosphamide combination therapy (CEX) as neoadjuvant chemotherapy (NAC) for HER-2-negative breast cancer and retrospectively analyzed its effectiveness and tolerability at our center. Methods: The inclusion criteria were presence of breast cancer negative for HER-2 and positive lymph node metastasis, or negative lymph node metastasis when tumor diameter was 20 mm or greater without distant metastasis. Additional inclusion criteria were a performance status of 0 or 1, an EF >60%, and an age of 75 years or less. Clinical outcomes were evaluated after 4 courses of epirubicin 80 mg/m2, cyclophosphamide 500 mg/m2 (administered every 3 weeks), and capecitabine 1,500 mg/m2 (administered for 2 weeks and withdrawn for 1 week). Results: A clinical benefit was noted in all 18 patients who received CEX as neoadjuvant chemotherapy during the period from 2009 through 2013. The clinical response rate was 83.3% (15/18), and the clinical complete response rate was 50%. Aesthetic outcomes of breast-conserving surgery were positive in all patients. Among patients with satisfactory outcomes, 33.3% had a pathologic complete response (triple-negative: 6, luminal: 0) and 68.8% were n0 (triple-negative: 8, luminal: 3). All patients with a pathologic complete response are presently alive, free of recurrence, and currently undergoing follow-up. Adverse events were classified as grade 2 or lower in all patients. Conclusions: CEX therapy administered as neoadjuvant chemotherapy could be useful for individualized treatment. In particular, this regimen was effective for triple-negative breast cancer.</p>
Journal
-
- Journal of Nippon Medical School
-
Journal of Nippon Medical School 87 (2), 73-79, 2020-04-15
The Medical Association of Nippon Medical School
- Tweet
Details 詳細情報について
-
- CRID
- 1390285300157926016
-
- NII Article ID
- 130007843307
-
- NII Book ID
- AA11563215
-
- ISSN
- 13473409
- 13454676
-
- PubMed
- 31776320
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- IRDB
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed